Related Experiment Video
Updated: Aug 30, 2026
Femoral Vascular Graft Implantation in a Swine Model to Test Small-Diameter Vascular Grafts
Published on: July 8, 2025
Abstract:
Xaliproden [SR 57746A, xaliprodene; Xaprila] is a compound that mimics the effects of nerve growth factor and is also a serotonin 5-HT1A receptor agonist. The drug was originated by Sanofi, and in mid-1999, Sanofi merged with Synthélabo to form Sanofi-Synthélabo. Phase III trials have been completed in patients with amyotrophic lateral sclerosis in Europe, the US and Canada. Xaliproden is at the phase II stage of clinical development for amyotrophic lateral sclerosis in Japan, where it also has orphan drug status for this indication.
More Related Videos
08:40Surgical Technique of the 3-Dimensional-printed Personalized Hip Implant for the Treatment of Canine Hip Dysplasia
Published on: April 19, 2024
03:49Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode
Published on: October 11, 2024